ArticleBrain and behavior2019
Serum interleukin-33 as a novel marker for long-term prognosis and recurrence in acute ischemic stroke patients.
Article in Brain and behavior, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Role of the IL-33/ST2 axis in cardiovascular disease: A systematic review and meta-analysis.PloS one · 2021Pooled it
- Immunological and Inflammatory Biomarkers in the Prognosis, Prevention, and Treatment of Ischemic Stroke: A Review of a Decade of Advancement.International journal of molecular sciences · 2025Review
- IL-33 in Ischemic Stroke: Brain vs. Periphery.Inflammation · 2025Review
- Expanding Role of Interleukin-1 Family Cytokines in Acute Ischemic Stroke.International journal of molecular sciences · 2024Review
- A one-year relapse prediction model for acute ischemic stroke (AIS) based on clinical big data.Heliyon · 2024Article
- Predictive value of low serum interleukin-33 levels in acute ischemic stroke outcomes.Frontiers in neurology · 2024Article
- IL-6 and stroke recurrence in ischemic stroke.Biomarkers in medicine · 2024Article
- Review
- The Relationship of Astrocytes and Microglia with Different Stages of Ischemic Stroke.Current neuropharmacology · 2023Review
- Prediction of Ischemic Stroke Recurrence Based on COX Proportional Risk Regression Model and Evaluation of the Effectiveness of Patient Intensive Care Interventions.Computational and mathematical methods in medicine · 2022Article
- Role of Interleukin-1 Receptor-Like 1 (ST2) in Cerebrovascular Disease.Neurocritical care · 2021Review
- The Clinical Significance of Serum IL-33 and sST2 Alterations in the Post-Stroke Depression.Journal of multidisciplinary healthcare · 2021Article
- Serum Interleukin-37 Increases in Patients after Ischemic Stroke and Is Associated with Stroke Recurrence.Oxidative medicine and cellular longevity · 2021Article
- Serum pentraxin 3 as a biomarker for prognosis of acute minor stroke due to large artery atherosclerosis.Brain and behavior · 2021Article
- Revealing the Common Mechanisms of Scutellarin in Angina Pectoris and Ischemic Stroke Treatment via a Network Pharmacology Approach.Chinese journal of integrative medicine · 2021Article
- Potential microglia-based interventions for stroke.CNS neuroscience & therapeutics · 2020Review
- Serum interleukin-33 as a novel marker for long-term prognosis and recurrence in acute ischemic stroke patients.Brain and behavior · 2019Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesInterleukin-33, a newly identified member of interleukin-1 family, had been confirmed to play a crucial role in regulating inflammatory responses in various disease. However, the exact role of interleukin-33 in the disease process of acute ischemic stroke still remains unclear. This study aims to demonstrate the relationship between interleukin-33 levels and long-term functional outcome as well as ischemic stroke recurrence.
methodsThree hundred and four first-ever acute ischemic stroke patients were recruited and basic information and history of all subjects taken within 72 hr on admission. The functional outcome was estimated by Barthel index. The multivariate logistic regression was used to analyze the prognosis, while the Cox proportional hazard model was applied to assess the recurrence risk.
resultsOut of 304 subjects, 259 patients successfully completed scheduled two-year follow-up. We found that higher interleukin-33 levels correlated positively with better prognosis as compared with those with lower interleukin-33 levels who presented with poorer outcome (62.45 ± 20.50 ng/ml vs. 51.58 ± 19.16 ng/ml, p < .001). After adjustment of all confounders, interleukin-33 was associated with the one-year prognosis with an adjusted odds ratio of 0.956 (95% confidence interval, 0.937-0.976, p < .001). Furthermore, interleukin-33 levels were also closely related to recurrent ischemic stroke with an adjusted hazard ratio of 0.979 (95% confidence interval, 0.961-0.997, p = .025).
conclusionsIL-33 can be used to predict the long-term outcomes and ischemic stroke recurrence in first-ever acute ischemic stroke patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.